Schistosomiasis haematobia: histopathological course determined by cystoscopy in a patient in whom praziquantel treatment failed

Silva, Iran Mendonça da; Filho, Edson Pereira; Thiengo, Roberto; Ribeiro, Paulo César; Conceição, Maria José; Panasco, Mônica S; Lenzi, Henrique Leonel

doi:10.1590/s0036-46652008000600006

Cited by 15 publications

(9 citation statements)

References 6 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sabah et al (103) hypothesized that people coming from areas where schistosomiasis is not endemic may lack an immunological component that has been shown to contribute to the activity of PZQ1 in experimental animals. Emergence of resistance of S. japonicum to PZQ1 has also received attention (101)(102)(103)(104)(105). However, despite large-scale and repeated use, the current efficacy of PZQ1 remains unchanged and it is highly effective at a curative dosage (a single dose of 40 mg/kg) in the main areas of China where schistosomiasis is endemic (106)(107)(108).…”

Section: Pzq Resistance In the Fieldmentioning

confidence: 99%

Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance

Vale

Gouveia

Rinaldi

et al. 2017

Antimicrob Agents Chemother

263

218

View full text Add to dashboard Cite

Schistosomiasis, a major neglected tropical disease, affects more than 250 million people worldwide. Treatment of schistosomiasis has relied on the anthelmintic drug praziquantel (PZQ) for more than a generation. PZQ is the drug of choice for the treatment of schistosomiasis; it is effective against all major forms of schistosomiasis, although it is less active against juvenile than mature parasites. A pyrazino-isoquinoline derivative, PZQ is not considered to be toxic and generally causes few or transient, mild side effects. Increasingly, mass drug administration targeting populations in sub-Saharan Africa where schistosomiasis is endemic has led to the appearance of reduced efficacy of PZQ, which portends the selection of drugresistant forms of these pathogens. The synthesis of improved derivatives of PZQ is attracting attention, e.g., in the (i) synthesis of drug analogues, (ii) rational design of pharmacophores, and (iii) discovery of new compounds from large-scale screening programs. This article reviews reports from the 1970s to the present on the metabolism and mechanism of action of PZQ and its derivatives against schistosomes.

show abstract

Section: Pzq Resistance In the Fieldmentioning

confidence: 99%

Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance

Vale

Gouveia

Rinaldi

et al. 2017

Antimicrob Agents Chemother

263

218

View full text Add to dashboard Cite

show abstract

“…On the other hand, several cases refractory to repeated PZQ administration have been reported in countries where the disease is nonendemic, i.e., imported cases (18)(19)(20). It is speculated that schistosomiasis patients, who are rare in countries where the disease is nonendemic, tend to be followed up by detailed examinations, such as cystoscopy and bladder biopsy sampling, in addition to detection of ova, thus enabling identification of refractory cases.…”

mentioning

confidence: 99%

Use of Cell-Free Circulating Schistosome DNA in Serum, Urine, Semen, and Saliva To Monitor a Case of Refractory Imported Schistosomiasis Hematobia

Kato-Hayashi

Yasuda²,

Yuasa³

et al. 2013

J Clin Microbiol

View full text Add to dashboard Cite

e This case of imported refractory schistosomiasis has highlighted the usefulness of cell-free parasite DNA as a diagnostic marker to assess active schistosome infection. In contrast to the rapid disappearance of ova in urine, parasite DNA remained persistent in several other specimen types even after the fourth treatment with praziquantel. This result was consistent with the presence of morphologically intact ova in bladder biopsy samples and with the corresponding symptoms. CASE REPORT

show abstract

“…Although few PZQ resistant isolates are detected in the field, a reduced susceptibility of the drug in S. mansoni has been widely found in many endemic foci, notably in African countries such as Egypt and Senegal 5 . Nowadays, there is no direct evidence of S. haematobium developing resistance to praziquantel; however, it has been reported that repeated standard treatment fails in schistosomiasis cases caused by S. haematobium infection 12 - 15 .…”

Section: Discussionmentioning

confidence: 99%

THE SUSCEPTIBILITY OF RECENT ISOLATES OF Schistosoma mansoni TO PRAZIQUANTEL

Mendonça

Feitosa

Veras

et al. 2016

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

Introduction: Schistosomiasis is a chronic disease caused by trematode flatworms of the genus Schistosoma and its control is dependent on a single drug, praziquantel (PZQ), but concerns over PZQ resistance have renewed interest in evaluating the in vitro susceptibility of recent isolates of Schistosoma mansoni to PZQ in comparison with well-established strains in the laboratory. Material and methods: The in vitro activity of PZQ (6.5-0.003 µg/mL) was evaluated in terms of mortality, reduced motor activity and ultrastructural alterations against S. mansoni. Results: After 3 h of incubation, PZQ, at 6.5 µg/mL, caused 100% mortality of all adult worms in the three types of recent isolates, while PZQ was inactive at concentrations of 0.08-0.003 µg/mL after 3 h of incubation. The results show that the SLM and Sotave isolates basically presented the same pattern of susceptibility, differing only in the concentration of 6.5 µg/mL, where deaths occurred from the range of 1.5 h in Sotave and just in the 3 h range of SLM. Additionally, this article presents ultrastructural evidence of rapid severe PZQ-induced surface membrane damage in S. mansoni after treatment with the drug, such as disintegration, sloughing, and erosion of the surface. Conclusion: According to these results, PZQ is very effective to induce tegument destruction of recent isolates of S. mansoni.

show abstract

Schistosomiasis haematobia: histopathological course determined by cystoscopy in a patient in whom praziquantel treatment failed

Cited by 15 publications

References 6 publications

Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance

Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance

Use of Cell-Free Circulating Schistosome DNA in Serum, Urine, Semen, and Saliva To Monitor a Case of Refractory Imported Schistosomiasis Hematobia

THE SUSCEPTIBILITY OF RECENT ISOLATES OF Schistosoma mansoni TO PRAZIQUANTEL

Contact Info

Product

Resources

About